2023
A Comprehensive Investigation of the Potential Role of Lipoproteins and Metabolite Profile as Biomarkers of Alzheimer’s Disease Compared to the Known CSF Biomarkers
Nasab A, Noorani F, Paeizi Z, Khani L, Banaei S, Sadeghi M, Shafeghat M, Shafie M, Mayeli M, Initiative T. A Comprehensive Investigation of the Potential Role of Lipoproteins and Metabolite Profile as Biomarkers of Alzheimer’s Disease Compared to the Known CSF Biomarkers. International Journal Of Alzheimer's Disease 2023, 2023: 3540020. PMID: 36936136, PMCID: PMC10019964, DOI: 10.1155/2023/3540020.Peer-Reviewed Original ResearchAssociated with Alzheimer's diseaseCerebrospinal fluidNegative groupCore biomarkersCerebrospinal fluid core biomarkersP-tauCorrelation of metabolitesMetabolites of patientsGlycolysis-related metabolitesAlzheimer's diseaseSubclasses of lipoproteinsPotential noninvasive markersAssociation of lipoproteinsCerebrospinal fluid tauAlzheimer's Disease Neuroimaging InitiativeFatty acidsNo significant differenceGene statusNoninvasive markerAD core biomarkersAD developmentBiomarkers of Alzheimer's diseasePositive groupSmall HDLAmino acidsCannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis
Nia A, Gibson C, Spriggs S, Jankowski S, DeFrancisco D, Swift A, Perkel C, Galynker I, Honrao C, Makriyannis A, Hurd Y. Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. Journal Of Psychopharmacology 2023, 37: 484-489. PMID: 36633290, DOI: 10.1177/02698811221148604.Peer-Reviewed Original ResearchConceptsEndocannabinoid systemCannabis usePlasma levelsHealthy individualsLow plasma levelsPlasma AEA levelsInpatient psychiatric unitNegative Syndrome ScaleRace/ethnicityUrine toxicologyAEA levelsPsychotic presentationsEndocannabinoid anandamideClinical significanceSelf-report questionnairesPsychiatric unitNegative groupPositive groupPsychotic symptomsMain endocannabinoidsSuppressive effectSyndrome ScaleN-oleoylethanolaminePsychosisFurther studies
2022
The telomere maintenance mechanism spectrum and its dynamics in gliomas
Kim S, Chowdhury T, Yu H, Kahng J, Lee C, Choi S, Kim K, Kang H, Lee J, Lee S, Won J, Kim K, Kim M, Lee J, Kim J, Kim Y, Kim T, Choi S, Phi J, Shin Y, Ku J, Lee S, Yun H, Lee H, Kim D, Kim K, Hur J, Park S, Kim S, Park C. The telomere maintenance mechanism spectrum and its dynamics in gliomas. Genome Medicine 2022, 14: 88. PMID: 35953846, PMCID: PMC9367055, DOI: 10.1186/s13073-022-01095-x.Peer-Reviewed Original ResearchConceptsTERT promoter mutationsTelomere maintenance mechanismTelomerase activityGlioma samplesTERT expressionPromoter mutationsCancer management strategiesSlow growth potentialC-circle assayCancer cell immortalityGlioma patientsSeparate cohortNegative groupGlioma progressionNanoString analysisTumor tissueTelomerase enzyme activityGliomasTumor cellsConclusionsThis studyALTATRX mutationsTelomerase activationATRX lossConsiderable proportion
2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphomaSafety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Zeidan A, Schiller G, Lin T, Becker P, Patel P, Wang E, Spira A, Tsai M, Ridinger M, Croucher P, Erlander M, Silberman S. Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Blood 2019, 134: 230. DOI: 10.1182/blood-2019-126262.Peer-Reviewed Original ResearchPositive ptsBiomarker positivityPhase 1bBristol-Myers SquibbSpeakers bureauObjective responseCount recoveryPreliminary efficacyBlood samplesNegative groupRelapsed/Refractory Acute Myeloid LeukemiaADC therapeuticsDay 1Jazz PharmaceuticalsRefractory acute myeloid leukemiaBoehringer IngelheimDaiichi SankyoIncomplete count recoveryPhase 1b/2 studyPreclinical AML modelsSubset of ptsLow-dose cytarabinePredictive gene expression signaturesDose-escalation trialPlatelet count recoveryOpioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment
McGinnis KA, Fiellin DA, Skanderson M, Hser YI, Lucas GM, Justice AC, Tate JP, Group F. Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment. Drug And Alcohol Dependence 2019, 204: 107511. PMID: 31546119, PMCID: PMC6993986, DOI: 10.1016/j.drugalcdep.2019.06.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV-1 RNADetectable HIV-1 RNAUninfected patientsAgonist treatmentVeterans Aging Cohort StudyResponsiveness of CD4Substance use disorder treatmentHealth effectsUrine toxicology resultsUrine toxicology testsAging Cohort StudyElectronic health record dataUse disorder treatmentHealth record dataPhysical health effectsRace/ethnicityOAT initiationCohort studyOpioid useBiomarker changesToxicology resultsNegative groupUninfected individualsDisorder treatment
2018
Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study
Breier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB. Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophrenia Research 2018, 206: 291-299. PMID: 30478008, DOI: 10.1016/j.schres.2018.11.002.Peer-Reviewed Original ResearchConceptsHSV-1Double-blind efficacy trialHerpes simplex virus 1 (HSV-1) infectionEarly phase schizophreniaSimplex virus 1 infectionVirus-1 infectionPathophysiology of schizophreniaPrimary endpointValacyclovir treatmentNegative subjectsRecent trialsVISTA studyEfficacy trialsLetter-Number Sequencing TestNegative groupPositive groupSevere formHerpes virusPositive symptomsMore impairmentTreatment resultsUS sitesCognitive deficitsNon-activated stateSchizophreniaOutcomes of repeat balloon assisted enteroscopy in small-bowel bleeding
Al-Bawardy B, Ramos G, Lennon R, Gorospe E, Song L, Bruining D, Alexander J, Coelho-Prabhu N, Fidler J, Rajan E. Outcomes of repeat balloon assisted enteroscopy in small-bowel bleeding. Endoscopy International Open 2018, 06: e694-e699. PMID: 29868634, PMCID: PMC5979197, DOI: 10.1055/a-0599-6085.Peer-Reviewed Original ResearchSmall bowel bleedingTherapeutic yieldAdverse eventsAntegrade routeOnly significant predictive factorChronic obstructive pulmonary diseaseSelf-limited abdominal painChronic kidney diseaseAdverse event ratesObstructive pulmonary diseaseSignificant predictive factorsCardiac comorbiditiesRepeat balloonAbdominal painSecondary outcomesPrimary outcomePulmonary diseaseRetrospective reviewPredictive factorsKidney diseaseBACKGROUND/Diagnostic yieldNegative groupMultivariate analysisEvent rates
2015
Clinical and laboratory characteristics associated with a high optical density anti-platelet factor 4 ELISA test
Lu B, Kudlowitz D, Gardner L. Clinical and laboratory characteristics associated with a high optical density anti-platelet factor 4 ELISA test. Journal Of Blood Medicine 2015, 6: 277-283. PMID: 26640392, PMCID: PMC4657791, DOI: 10.2147/jbm.s90179.Peer-Reviewed Original ResearchHigh-positive groupHeparin-Induced ThrombocytopeniaPF4 ELISADefinitive heparin-induced thrombocytopeniaRetrospective chart review of patientsChart review of patientsDiagnose heparin-induced thrombocytopeniaReview of patientsLow-positive groupRetrospective chart reviewImmune-mediated disordersFisher's exact testWilcoxon rank sum testUrban academic institutionHigh-positive patientsRank sum testNegative patientsLaboratory characteristicsPositive patientsClinical characteristicsClinical featuresExact testNegative groupClinical variablesHospital days
2009
The Clinical Significance of Antiphospholipid Antibodies in Korean Children with Henoch-Schönlein Purpura
Park E, Baek J, Shin J, Lee J, Kim H. The Clinical Significance of Antiphospholipid Antibodies in Korean Children with Henoch-Schönlein Purpura. Childhood Kidney Diseases 2009, 13: 146-152. DOI: 10.3339/jkspn.2009.13.2.146.Peer-Reviewed Original ResearchHenoch-Schonlein purpuraClinical significance of antiphospholipid antibodiesSignificance of antiphospholipid antibodiesLA-positive groupAPL AbsAntiphospholipid antibodiesClinical significanceNegative groupDiagnosis of Henoch-Schonlein purpuraPathogenesis of Henoch-Schonlein purpuraPositive groupGlycoprotein I antibodiesErythrocyte sedimentation rateAnti-cardiolipin antibodiesC-reactive proteinKorean childrenAcute inflammatory processEULAR/PRES criteriaAbdominal painRenal involvementC4 levelsI antibodiesInflammatory processMedical recordsClinical diagnosis
1987
The triage role of fine needle aspiration biopsy of palpable breast masses. Diagnostic accuracy and cost-effectiveness.
Silverman J, Lannin D, O'Brien K, Norris H. The triage role of fine needle aspiration biopsy of palpable breast masses. Diagnostic accuracy and cost-effectiveness. Acta Cytologica 1987, 31: 731-6. PMID: 3425133.Peer-Reviewed Original ResearchConceptsFine-needle aspiration biopsyNeedle aspiration biopsyFalse-positive diagnosesFNA biopsyTriage roleMedical CenterAspiration biopsyFrozen section confirmationFrozen section biopsyTertiary medical centerPalpable breast massesFNA breast biopsyOutpatient biopsyHistologic confirmationExcisional biopsyLocal anesthesiaPrimary diagnosisSuspicious diagnosisInpatient proceduresBreast carcinomaNegative groupPositive groupBiopsyInsufficient diagnosisBreast biopsy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply